Keppra (Epilepsy) - Forecast and Market Analysis to 2022

Date: February 25, 2013
Pages: 53
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: KB287BBD550EN
Leaflet:

Download PDF Leaflet

Keppra (Epilepsy) - Forecast and Market Analysis to 2022
Keppra (Epilepsy) - Forecast and Market Analysis to 2022

SUMMARY

GlobalData has released its new PharmaPoint Drug Evaluation report, “Keppra (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Keppra (levetiracetam) is an approved first-in-class AED developed and marketed by UCB. The drug received FDA approval in November 1999, and EU approval in September 2000. Levetiracetam is also marketed under the brand E Keppra in Japan. Keppra is formulated as film-coated tablets, as a solution for oral administration, and as a solution concentrate for infusion. It has been the most successful of all the newer AEDs introduced in the last 20 years, and its blockbuster sales have propelled the relatively small Belgian pharmaceutical company UCB into the big leagues (Shorvon, 2009). Levetiracetam works by selectively binding to SV2A. SV2A is involved in the release of neurotransmitters, and binding it may help reduce excessive neurotransmitter release and stabilize electrical activity in the brain, thus preventing seizures. Kepprahas action against many types of generalized as well as partial seizures, and has also been shown to be effective in some patients in whom other drugs are ineffective. Unlike many AEDs, Keppra has an alerting rather than a sedating effect, which may contribute to its popularity (Shorvon, 2009).

SCOPE
  • Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Keppra including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Keppra for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Chaina and India
REASONS TO BUY
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Keppra performance
  • Obtain sales forecast for Keppra from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Chaina and India)
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports

3 DISEASE OVERVIEW

3.1 Classification of Seizures
3.2 Etiology and Pathophysiology
  3.2.1 Etiology
  3.2.2 Pathophysiology
  3.2.3 Prognosis
  3.2.4 Quality of Life

4 DISEASE MANAGEMENT

4.1 Diagnosis
4.2 Treatment Guidelines
4.3 Clinical Practice

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment

6 KEPPRA (LEVETIRACETAM)

6.1 Overview
6.2 Therapeutic Role
6.3 Efficacy
6.4 Safety
6.5 SWOT Analysis
6.6 Forecast

7 APPENDIX

7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Prevalent Epilepsy Patients
  7.4.2 Percent Drug-Treated Patients
  7.4.3 General Pricing Assumptions
  7.4.4 Individual Drug Assumptions
  7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
  7.7.1 Authors
  7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Contact Us
7.10 Disclaimer

LIST OF TABLES

Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
Table 2: Classification of Seizures
Table 3: Etiology of Epilepsy According to Age
Table 4: Etiology of Partial Seizures
Table 5: Etiology of Generalized Seizures
Table 6: Some of the Genes Involved in Epilepsy
Table 7: Summary of Diagnostic Tools for Epilepsy
Table 8: Treatment Guidelines for Epilepsy
Table 9: AED Options by Seizure Type
Table 10: Top Three AEDs Prescribed for Epilepsy by Market
Table 11: Types of Epilepsy Surgery
Table 12: Leading Treatments for Epilepsy, 2012
Table 13: Product Profile – Keppra
Table 14: Keppra SWOT Analysis, 2012
Table 15: Global Sales Forecasts ($m) for Keppra (levetiracetam), 2012–2022
Table 16: Physicians Surveyed, By Country

LIST OF FIGURES

Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
Figure 2: Mechanisms of Action of AEDs at the Synapse
Figure 3: AED Selection Based on Comorbidity

Ask Your Question

Keppra (Epilepsy) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: